Adicet Bio, Inc. (ACET)
4.57
-0.57
(-11.09%)
USD |
NASDAQ |
Oct 16, 16:00
4.60
+0.03
(+0.66%)
After-Hours: 20:00
Adicet Bio Enterprise Value : -62.55M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | -62.55M |
| October 15, 2026 | -57.22M |
| October 14, 2026 | -59.56M |
| October 13, 2026 | -57.50M |
| October 12, 2026 | -53.57M |
| October 09, 2026 | -52.82M |
| October 08, 2026 | -51.60M |
| October 07, 2026 | -47.48M |
| October 06, 2026 | -46.83M |
| October 05, 2026 | -44.77M |
| October 02, 2026 | -44.49M |
| October 01, 2026 | -43.18M |
| September 30, 2026 | -38.50M |
| September 29, 2026 | -41.40M |
| September 28, 2026 | -45.89M |
| September 25, 2026 | -20.90M |
| September 24, 2026 | -27.92M |
| September 23, 2026 | -25.86M |
| September 22, 2026 | -19.73M |
| September 21, 2026 | -21.74M |
| September 18, 2026 | -19.40M |
| September 17, 2026 | -20.99M |
| September 16, 2026 | -20.62M |
| September 15, 2026 | -25.72M |
| September 14, 2026 | -14.53M |
| Date | Value |
|---|---|
| September 11, 2026 | -16.22M |
| September 10, 2026 | -16.12M |
| September 09, 2026 | -16.03M |
| September 08, 2026 | -14.25M |
| September 04, 2026 | -15.56M |
| September 03, 2026 | -17.06M |
| September 02, 2026 | -18.65M |
| September 01, 2026 | -18.65M |
| August 31, 2026 | -23.89M |
| August 28, 2026 | -20.52M |
| August 27, 2026 | -20.99M |
| August 26, 2026 | -21.55M |
| August 25, 2026 | -21.08M |
| August 24, 2026 | -22.02M |
| August 21, 2026 | -19.30M |
| August 20, 2026 | -17.53M |
| August 19, 2026 | -16.50M |
| August 18, 2026 | -20.05M |
| August 17, 2026 | -23.52M |
| August 14, 2026 | -26.89M |
| August 13, 2026 | -28.01M |
| August 12, 2026 | -28.01M |
| August 11, 2026 | -28.29M |
| August 10, 2026 | -29.42M |
| August 07, 2026 | -30.63M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.409B |
| Alnylam Pharmaceuticals, Inc. | 30.68B |
| Anika Therapeutics, Inc. | 254.23M |
| Savara, Inc. | 771.40M |
| Vericel Corp. | 1.986B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.36M |
| Total Expenses (Quarterly) | 21.36M |
| EPS Diluted (Quarterly) | -1.988 |
| Earnings Yield | -252.4% |
| Normalized Earnings Yield | -252.36 |